Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
高配当
同社は高配当銘柄であり、最新の配当性向は11.81%です。
安定配当
同社は過去5年間にわたり継続的に配当を実施しており、最新の配当性向は11.81%です。
割高
同社の最新のPEは20.33で、過去3年間の水準と比較して高値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は117.02M株で、前四半期比で7.30%減少しています。
バンガードが保有
スター投資家バンガードは本銘柄を7.88M株保有しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は0.86です。